Drug Profile

Z 335

Latest Information Update: 31 Oct 2005

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Zeria
Class Antiplatelets; Vascular disorder therapies
Mechanism of Action Thromboxane A2 receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Arterial occlusive disorders

Most Recent Events

24 Oct 2005 Discontinued - Phase-II for Arterial occlusive disorders in Japan (PO)
30 Jul 2002 A preclinical study has been added to the pharmacokinetics and Ischaemic Heart Disease and Thromboses pharmacodynamics sections
26 Aug 1999 Phase-II clinical trials for Arterial occlusive disorders in Japan (PO)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com